guest ::
| Home > Publications database > A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl. > print |
| Home > Publications database > A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl. > print |
| 001 | 241137 | ||
| 005 | 20240229154915.0 | ||
| 024 | 7 | _ | |a 10.1016/j.celrep.2023.112049 |2 doi |
| 024 | 7 | _ | |a pmid:36719797 |2 pmid |
| 024 | 7 | _ | |a 2211-1247 |2 ISSN |
| 024 | 7 | _ | |a 2639-1856 |2 ISSN |
| 024 | 7 | _ | |a altmetric:141972856 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-00250 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Triller, Gianna |0 P:(DE-He78)b22859d95abd0c9334442dfafdf9dc01 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl. |
| 260 | _ | _ | |a [New York, NY] |c 2023 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1675327529_2339 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:D150#LA:D150# |
| 520 | _ | _ | |a Poorly immunogenic small molecules pose challenges for the production of clinically efficacious vaccines and antibodies. To address this, we generate an immunization platform derived from the immunogenic surface coat of the African trypanosome. Through sortase-based conjugation of the target molecules to the variant surface glycoprotein (VSG) of the trypanosome surface coat, we develop VSG-immunogen array by sortase tagging (VAST). VAST elicits antigen-specific memory B cells and antibodies in a murine model after deploying the poorly immunogenic molecule fentanyl as a proof of concept. We also develop a single-cell RNA sequencing (RNA-seq)-based computational method that synergizes with VAST to specifically identify memory B cell-encoded antibodies. All computationally selected antibodies bind to fentanyl with picomolar affinity. Moreover, these antibodies protect mice from fentanyl effects after passive immunization, demonstrating the ability of these two coupled technologies to elicit therapeutic antibodies to challenging immunogens. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a CP: Immunology |2 Other |
| 650 | _ | 7 | |a Trypanosoma brucei |2 Other |
| 650 | _ | 7 | |a antibody repertoire analysis |2 Other |
| 650 | _ | 7 | |a fentanyl |2 Other |
| 650 | _ | 7 | |a humoral immunity |2 Other |
| 650 | _ | 7 | |a immunological memory |2 Other |
| 650 | _ | 7 | |a opioid overdose |2 Other |
| 650 | _ | 7 | |a sortase |2 Other |
| 650 | _ | 7 | |a variant surface glycoprotein |2 Other |
| 700 | 1 | _ | |a Vlachou, Evi P |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Hashemi, Hamidreza |0 P:(DE-He78)8a54ae86df2d4a9f54a26e80554e806e |b 2 |
| 700 | 1 | _ | |a van Straaten, Monique |0 P:(DE-He78)604bb0ebdb4e4aa550668663597c9ec8 |b 3 |u dkfz |
| 700 | 1 | _ | |a Zeelen, Johan P |0 P:(DE-He78)60be168620c9910e4bb9c2b99d8db56f |b 4 |u dkfz |
| 700 | 1 | _ | |a Kelemen, Yosip |b 5 |
| 700 | 1 | _ | |a Baehr, Carly |b 6 |
| 700 | 1 | _ | |a Marker, Cheryl L |b 7 |
| 700 | 1 | _ | |a Ruf, Sandra |0 P:(DE-He78)987a16a93296d4a043a1b2337d224b53 |b 8 |u dkfz |
| 700 | 1 | _ | |a Svirina, Anna |0 P:(DE-He78)eba50148f2b8e408c7df5d753c698e3a |b 9 |u dkfz |
| 700 | 1 | _ | |a Chandra, Monica |0 P:(DE-He78)97b2ee6c4015e70e559ff4b9ab637e72 |b 10 |u dkfz |
| 700 | 1 | _ | |a Urban, Katharina |0 P:(DE-He78)9cafc6ecff7e1f32c9d4644c841740cb |b 11 |u dkfz |
| 700 | 1 | _ | |a Gkeka, Anastasia |0 P:(DE-He78)2860863e19e5f3ec9efeced72d895714 |b 12 |u dkfz |
| 700 | 1 | _ | |a Kruse, Sebastian |b 13 |
| 700 | 1 | _ | |a Baumann, Andreas |0 P:(DE-He78)732ee924fba787fd2f9235b0a960ca53 |b 14 |
| 700 | 1 | _ | |a Miller, Aubry K |0 P:(DE-He78)f0af962ddbc82430e947390b2f3f6e49 |b 15 |u dkfz |
| 700 | 1 | _ | |a Bartel, Marc |b 16 |
| 700 | 1 | _ | |a Pravetoni, Marco |b 17 |
| 700 | 1 | _ | |a Stebbins, C Erec |0 P:(DE-He78)3e1497ece09f8d2c69efc8b106a08f2b |b 18 |u dkfz |
| 700 | 1 | _ | |a Papavasiliou, F Nina |0 P:(DE-He78)79dbda58d51b613a0a421f579d2dfed3 |b 19 |u dkfz |
| 700 | 1 | _ | |a Verdi, Joseph Peter |0 P:(DE-He78)e13953968ed53b7fcae1139ac9ea7583 |b 20 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1016/j.celrep.2023.112049 |g Vol. 42, no. 2, p. 112049 - |0 PERI:(DE-600)2649101-1 |n 2 |p 112049 |t Cell reports |v 42 |y 2023 |x 2211-1247 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:241137 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)b22859d95abd0c9334442dfafdf9dc01 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)604bb0ebdb4e4aa550668663597c9ec8 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)60be168620c9910e4bb9c2b99d8db56f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)987a16a93296d4a043a1b2337d224b53 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)eba50148f2b8e408c7df5d753c698e3a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)97b2ee6c4015e70e559ff4b9ab637e72 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)9cafc6ecff7e1f32c9d4644c841740cb |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)2860863e19e5f3ec9efeced72d895714 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)732ee924fba787fd2f9235b0a960ca53 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)f0af962ddbc82430e947390b2f3f6e49 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)3e1497ece09f8d2c69efc8b106a08f2b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-He78)79dbda58d51b613a0a421f579d2dfed3 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 20 |6 P:(DE-He78)e13953968ed53b7fcae1139ac9ea7583 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CELL REP : 2022 |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-05-02T08:49:39Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-05-02T08:49:39Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-05-02T08:49:39Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-26 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CELL REP : 2022 |d 2023-10-26 |
| 920 | 2 | _ | |0 I:(DE-He78)D150-20160331 |k D150 |l D150 Immundiversität |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)D150-20160331 |k D150 |l D150 Immundiversität |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D150-20160331 |k D150 |l D150 Immundiversität |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D160-20160331 |k D160 |l D160 Strukturbiologie von Infektion und Immunität |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)A390-20160331 |k A390 |l AG Wirkstoffforschung |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D150-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D160-20160331 |
| 980 | _ | _ | |a I:(DE-He78)A390-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|